|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM41A |
Gene summary for TMEM41A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM41A | Gene ID | 90407 |
| Gene name | transmembrane protein 41A | |
| Gene Alias | 2900010K02Rik | |
| Cytomap | 3q27.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q96HV5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90407 | TMEM41A | LZE2T | Human | Esophagus | ESCC | 3.83e-02 | 5.57e-01 | 0.082 |
| 90407 | TMEM41A | LZE4T | Human | Esophagus | ESCC | 3.16e-20 | 7.32e-01 | 0.0811 |
| 90407 | TMEM41A | LZE7T | Human | Esophagus | ESCC | 3.34e-10 | 7.99e-01 | 0.0667 |
| 90407 | TMEM41A | LZE8T | Human | Esophagus | ESCC | 1.32e-14 | 6.09e-01 | 0.067 |
| 90407 | TMEM41A | LZE20T | Human | Esophagus | ESCC | 2.23e-16 | 6.83e-01 | 0.0662 |
| 90407 | TMEM41A | LZE22T | Human | Esophagus | ESCC | 6.82e-03 | 7.13e-01 | 0.068 |
| 90407 | TMEM41A | LZE24T | Human | Esophagus | ESCC | 3.33e-36 | 1.25e+00 | 0.0596 |
| 90407 | TMEM41A | LZE21T | Human | Esophagus | ESCC | 3.45e-08 | 8.34e-01 | 0.0655 |
| 90407 | TMEM41A | LZE6T | Human | Esophagus | ESCC | 4.54e-04 | 3.74e-01 | 0.0845 |
| 90407 | TMEM41A | P1T-E | Human | Esophagus | ESCC | 4.23e-15 | 1.10e+00 | 0.0875 |
| 90407 | TMEM41A | P2T-E | Human | Esophagus | ESCC | 4.08e-79 | 1.38e+00 | 0.1177 |
| 90407 | TMEM41A | P4T-E | Human | Esophagus | ESCC | 1.05e-43 | 1.22e+00 | 0.1323 |
| 90407 | TMEM41A | P5T-E | Human | Esophagus | ESCC | 4.88e-23 | 4.96e-01 | 0.1327 |
| 90407 | TMEM41A | P8T-E | Human | Esophagus | ESCC | 8.77e-41 | 8.51e-01 | 0.0889 |
| 90407 | TMEM41A | P9T-E | Human | Esophagus | ESCC | 5.34e-27 | 6.71e-01 | 0.1131 |
| 90407 | TMEM41A | P10T-E | Human | Esophagus | ESCC | 5.89e-39 | 7.73e-01 | 0.116 |
| 90407 | TMEM41A | P11T-E | Human | Esophagus | ESCC | 1.59e-18 | 1.25e+00 | 0.1426 |
| 90407 | TMEM41A | P12T-E | Human | Esophagus | ESCC | 3.46e-27 | 6.91e-01 | 0.1122 |
| 90407 | TMEM41A | P15T-E | Human | Esophagus | ESCC | 2.38e-45 | 1.12e+00 | 0.1149 |
| 90407 | TMEM41A | P16T-E | Human | Esophagus | ESCC | 1.58e-31 | 6.22e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM41A | SNV | Missense_Mutation | c.662C>G | p.Thr221Ser | p.T221S | Q96HV5 | protein_coding | deleterious(0.01) | probably_damaging(0.928) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | |
| TMEM41A | SNV | Missense_Mutation | novel | c.202N>C | p.Tyr68His | p.Y68H | Q96HV5 | protein_coding | tolerated(0.06) | benign(0.059) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| TMEM41A | SNV | Missense_Mutation | novel | c.172N>A | p.Leu58Ile | p.L58I | Q96HV5 | protein_coding | deleterious(0.01) | probably_damaging(0.962) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TMEM41A | SNV | Missense_Mutation | novel | c.161N>C | p.Leu54Pro | p.L54P | Q96HV5 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AA-3660-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM41A | SNV | Missense_Mutation | c.686C>T | p.Ala229Val | p.A229V | Q96HV5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| TMEM41A | SNV | Missense_Mutation | novel | c.671N>C | p.Lys224Thr | p.K224T | Q96HV5 | protein_coding | deleterious(0.01) | benign(0.155) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| TMEM41A | deletion | Frame_Shift_Del | c.723delN | p.Lys241AsnfsTer9 | p.K241Nfs*9 | Q96HV5 | protein_coding | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
| TMEM41A | insertion | Frame_Shift_Ins | novel | c.590_591insGCAGTACTTG | p.Asn197LysfsTer31 | p.N197Kfs*31 | Q96HV5 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TMEM41A | insertion | Frame_Shift_Ins | rs766594251 | c.467dupT | p.Leu158IlefsTer40 | p.L158Ifs*40 | Q96HV5 | protein_coding | TCGA-AG-4007-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| TMEM41A | SNV | Missense_Mutation | novel | c.523N>A | p.Ala175Thr | p.A175T | Q96HV5 | protein_coding | deleterious(0.02) | benign(0.41) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |